Actively Recruiting
Recurrent Liver Cancer: Reconceptualization and Reevaluation
Led by Nanjing Medical University · Updated on 2024-12-12
300
Participants Needed
1
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating a specific protein to see if it can act as a new marker for detecting the return of liver cancer. The study focuses on patients with recurrent liver cancer and compares them to those with primary liver cancer. The main goal is to find out if higher levels of this protein are linked to liver cancer coming back and if it can be used to monitor recurrence early. The study divides participants into two groups: a training set of 50 recurrent liver cancer patients with high protein levels and a validation set of 250 recurrent liver cancer patients to confirm findings. Participants will provide blood samples and undergo regular follow-up visits. Clinical data such as medical history and treatment outcomes will also be collected and carefully checked for quality and accuracy. Participants will be monitored through blood tests and follow-up visits every few months to collect data on their health and protein levels. Researchers will measure the protein's accuracy in detecting cancer return, along with survival rates and time until disease progression over up to 5 years. Personal information will be securely stored, and ethical standards are followed throughout the study.
CONDITIONS
Brief Title
Recurrent Liver Cancer: Reconceptualization and Reevaluation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with primary hepatocellular carcinoma or non-HCC liver cancer
- Able to read, understand, and sign the informed consent form
- Agree to provide blood samples and have good clinical compliance
- Complete clinical information available, including unique ID, age, gender, and diagnostic imaging or pathology results
You will not qualify if you...
- Pregnant women
- Patients who have received organ transplantation
- Non-HCC patients diagnosed with other tumors
- Patients with primary hepatocellular carcinoma complicated by other tumors
- Judged by the researcher as not meeting the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants are observed through collection of clinical information including demographics, medical history, treatment regimens, and follow-up outcomes over time.
Follow-up visits every 3 months for the first 2 years, then every 6 months until study completion
Trial Site Locations
Total: 1 location
1
The Second Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210000
Actively Recruiting
Research Team
Z
zhang yewei, doctor
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here